3/19/12 Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH 
Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, is proud to announce that it has received a second round of funding from the National Institutes of Health for its work in inflammatory bowel disease. Read more.

3/16/12 Embera NeuroTherapeutics Publish Paper Supporting Its Smoking Cessation Treatment
Embera NeuroTherapeutics Inc., a specialty pharmaceutical company developing novel treatments for smoking cessation and other addictions, announced today the publication of results from a preclinical study of the combination use of metyrapone and oxazepam to treat nicotine addiction. Read more.

11/10/11 - Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract,announced today that the company completed its first close of $2.2 million of a Series A angelled financing. Cherrystone Angels of Providence, Rhode Island led the round, with participation from Boston Harbor Angels and other undisclosed individuals.  Read more.

11/3/11 - Dom Lombardi, CEO of the Institute for Pediatric Innovation, Named Purpose Prize Fellow
The Institute for Pediatric Innovation and Civic Ventures today announced that the Institute’s CEO Donald Lombardi is a 2011 Purpose Prize fellow. Lombardi is recognized as a social entrepreneur who is using his experience and vision to make an extraordinary impact on one of our society’s biggest challenges in his encore career – which combines meaning, professional engagement, and social impact in the second half of life.  Read more.

8/15/11 - Embera's $4.5M Series A financing aims to break smoking addiction
Embera NeuroTherapeutics Inc., a pharmaceutical firm with offices in Boston and Shreveport, La., has pulled in a $4.5 million Series A funding round to support its treatments for ending smoking addition, as well as other addictions, the company reported in a news release today.  Read more.

8/3/11 - Avaxia Biologics, Inc. awarded BARDA contract for Therapeutic Countermeasure to help the nation respond to a radiological emergency
Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.  Read more.

5/11/11 - TEI Biosciences Wins SBANE 2011 New England Innovation Award
TEI Biosciences Inc. was named a winner of the prestigious New England Innovation Award sponsored by the Smaller Business Association of New England (SBANE). TEI was selected from 185 innovative companies and was one of six winners in the for-profit category. Read more.

5/3/11 - Theracos moves from California to Massachusetts
Theracos Inc., a privately held biotech research and development company, said today that it has relocated from Sunnyvale, Calif., to Marlborough. Read more.

3/11/11 - Institute for Pediatric Innovation and Children's Medical Center Dallas join forces
Children's Medical Center Dallas is the latest highly regarded hospital to join the Institute for Pediatric Innovation's Consortium of Pediatric Hospitals. These progressive children's hospitals work closely with Pediatric Innovation to identify new medical devices and drug formulations that specifically address the health needs of babies and children. Read more.

1/24/11 -  NEHI receives grant from California HealthCare Foundation
NEHI announced today that it has been awarded a grant from the California HealthCare Foundation (CHCF) to study the potential of using telemedicine to improve the care delivered in intensive care units (ICUs) in California. The $214,000 grant will be used to assess the state's current ICU capacity and examine whether tele-ICU technology can expand the availability of trained critical care specialists. Read more.